Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007 Nov; 107(2):177-85.
View in:
PubMed
subject areas
Aged
Aged
Aged, 80 and over
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Antineoplastic Combined Chemotherapy Protocols
Carcinosarcoma
Carcinosarcoma
Chemotherapy, Adjuvant
Chemotherapy, Adjuvant
Cisplatin
Cisplatin
Disease-Free Survival
Disease-Free Survival
Drug Administration Schedule
Drug Administration Schedule
Female
Female
Humans
Humans
Hysterectomy
Hysterectomy
Ifosfamide
Ifosfamide
Incidence
Incidence
Mesna
Mesna
Middle Aged
Middle Aged
Neoplasm Recurrence, Local
Neoplasm Recurrence, Local
Neoplasm Staging
Neoplasm Staging
Prognosis
Prognosis
Prospective Studies
Prospective Studies
Protective Agents
Protective Agents
Radiotherapy, Adjuvant
Radiotherapy, Adjuvant
Risk Factors
Risk Factors
Survival Analysis
Survival Analysis
Treatment Failure
Treatment Failure
Treatment Outcome
Treatment Outcome
Uterine Neoplasms
Uterine Neoplasms
authors with profiles
Robert S Mannel